|
|
|
| home > directory > CMAB Biopharma |
|
|
 PHARMACEUTICAL INDUSTRY DIRECTORY |
CMAB Biopharma |
 |
| |
|
CMAB Biopharma is a full service, pure play Contract Development and Manufacturing Organisation (CDMO), which provides bespoke solutions for mammalian cell culture derived antibodies and recombinant proteins.
Our mission is to be the biologic CDMO of choice for biopharma companies from around the world by leveraging our state-of-the-art manufacturing facility, our large-scale production capacity and our ability to meet international quality requirements.
Established in 2017 with strong financial backing from our three main shareholders (C-Bridge Capital, CD Capital and BioBay), our 10,500 m2 (112,980 ft2) facility is located just outside of Shanghai in Suzhou, China. We have grown rapidly in 18 months to 175 full time employees with international offices founded in Switzerland, Toronto and Singapore. Our senior management is composed of experts with experience working in large international biotechnology organisations such as Genentech, Eli Lilly, Pfizer, Amgen and Janssen as well as CDMOs such as Lonza, Wuxi, Therapure and MabPlex.
At CMAB Biopharma, we currently provide expertise and experience in cell line development, process and analytical development, drug substance (DS) CGMP manufacturing as well as fully automated aseptic fill / finish along with lyophilisation. Our process development and analytical development labs are fully equipped with the latest equipment including a mass spectrometer unit for protein characterisation. Our four parallel upstream suites offer flexible CGMP production scales using multiple single use bioreactors (SUBs) ranging from 200 to 2,000 L volumes. Finally, we can provide our clients with lot release testing and standardised stability studies.
Our operational protocols and quality standards comply fully with FDA, EMA and NMPA guidelines, which enables CMAB Biopharma to produce CGMP material for both domestic as well as global clients. In addition, our quality standards align to the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S), International Committee on Harmonization (ICH) and World Health Organisation (WHO) guidelines.
To learn more about CMAB Biopharma or to get in contact with us directly, please visit www.cmabbio.com/en or write to us at hello@cmabbio.com. We look forward to hearing from you.
|
|
|
|
|
|
| |
|
|
|
|
|
 |
Industry Events |
 |
SCOPE Summit for Clinical Ops Executives
18-21 February 2020, Hyatt Regency, Orlando, Florida, US
Celebrating its 11th successful year,
SCOPE Summit 2020 takes place February 18-21 in Orlando, FL. Over the course of
four stimulating days of in-depth discussions in 20 different conferences, 3
plenary keynote sessions, the annual Participant Engagement Awards, and the
ever-popular interactive breakout discussions, the programming focuses on advances
and innovative solutions in all aspects of clinical trial planning, management
and operations
More info >> |
|
 |
News and Press Releases |
 |
Gerresheimer manufactures sustainable primary plastic packaging
Düsseldorf, January 14, 2020. Consumers are placing great importance on eco-friendly plastic packaging products, specifically – and increasingly – on sustainable packaging solutions that can be disposed of in an environmentally friendly way. At Gerresheimer, therefore, innovation and environmental protection go hand in hand. A pioneer in the quest for greater sustainability, Gerresheimer offers an extensive standard range of plastic packaging and devices customized solutions made from PET, R-PET, and BIO-PET plastics.
More info >> |
|
|
|
